Literature DB >> 11372728

The pathogenesis of chronic myeloproliferative diseases.

A Tefferi1.   

Abstract

Chronic myeloproliferative disorders are operationally classified to include essential thrombocythemia, polycythemia vera, and agnogenic myeloid metaplasia. In most cases, clonal hematopoiesis, involving all 3 myeloid lineages, can be demonstrated. However, the underlying molecular lesions that are responsible for disease initiation and progression remain elusive. There are ongoing efforts to clarify the pathogenetic role of cytokines, bone marrow stromal cells and molecules, and intracellular aberrations in either signal transduction or apoptosis. This review discusses some of the current and past observations regarding the pathogenesis of chronic myeloproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372728     DOI: 10.1007/bf02981934

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  109 in total

1.  Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells.

Authors:  X Sui; S B Krantz; Z Zhao
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  Evidence for integrin receptor involvement in megakaryocyte-fibroblast interaction: a possible pathomechanism for the evolution of myelofibrosis.

Authors:  B Schmitz; J Thiele; F Otto; P Farahmand; F Henze; S Frimpong; C Wickenhauser; R Fischer
Journal:  J Cell Physiol       Date:  1998-09       Impact factor: 6.384

3.  Letter: Bone-marrow responses in polycythemia vera.

Authors:  J F Prchal; A A Axelrad
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

4.  Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera.

Authors:  C H Dai; S B Krantz; S T Sawyer
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

5.  Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis.

Authors:  T Ruutu; S Partanen; S Knuutila
Journal:  Scand J Haematol       Date:  1983-09

6.  A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications.

Authors:  C N Harrison; R E Gale; S J Machin; D C Linch
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

7.  Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrombocythaemia.

Authors:  G Zauli; G Visani; L Catani; N Vianelli; L Gugliotta; S Capitani
Journal:  Br J Haematol       Date:  1993-01       Impact factor: 6.998

8.  Bone marrow hypervascularity in patients with myelofibrosis identified by infra-red thermography.

Authors:  T P Baglin; J Crocker; A Timmins; S Chandler; B J Boughton
Journal:  Clin Lab Haematol       Date:  1991

9.  Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.

Authors:  A Caenazzo; F Pietrogrande; G Polato; E Piva; M Masiero; D Sgarabotto; A Girolami
Journal:  Acta Haematol       Date:  1989       Impact factor: 2.195

10.  Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta.

Authors:  P Rameshwar; T N Denny; D Stein; P Gascón
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

View more
  1 in total

1.  Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.

Authors:  Oliver Bock; Guntram Büsche; Christina Koop; Sabine Schröter; Thomas Buhr; Hans Kreipe
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.